|Articles|August 20, 2012

Considerations for the Development and Manufacturing of Biosimilars [Presentation]

This content is provided by Amgen.

Divided into 3 sections, this presentation provides insight into the complexities of developing and manufacturing biologics and discusses considerations for the development of biosimilars.

Please click the image below to view the presentation.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Considerations for the Development and Manufacturing of Biosimilars [Presentation]

Related Content

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis